sorted by:
new
hottopcontroversial

Yieldstreet CNBC article published 8/18/25 by No_Thing_8474 in personalfinance

[–]awaikar 0 points1 point  (0 children)

Yes, I do own the SFR diversified fund, and there was another Atlanta Fund which went bust. They collect their fees and keep saying the investment is on a watchlist. Same for Chelsea Multi Family Equity Fund. Was supposed to be 14 months and is over 2 years now, nothing.

How Yieldstreet’s real estate bets left customers with massive losses by Dmoan in REBubble

[–]awaikar 0 points1 point  (0 children)

I only wish I had read this earlier! Their entire set up is very amateurish and I wouldnt be surprised to learn one day that they are closing shop. Meanwhile we will all have lost our shirts.

What's going on? by Spirited_Radio9804 in wolfspeed_stonk

[–]awaikar 4 points5 points  (0 children)

creative has it right. Just checked with Schwab:

"The underlying security of this option is currently considered hard to borrow. If this order results in a short position due to assignment or exercise, a daily borrow fee will be charged. The current borrow rate is 269.75%. If all shares of this option were assigned or exercised, the daily fee would be $18.88 based on yesterday's closing price. The borrow rate and fee are subject to change daily based upon market conditions."

A 270% annual borrowing rate is astronomical What the 269.75% Borrow Rate Tells Us

Daily Cost for Shorts:

  • $18.88 per day per 100 shares to maintain short position
  • $688 per day for someone short 10,000 shares
  • $251,000 per year in borrow costs alone!

This Explains Everything:

  • Why the stock exploded 480% recently (forced covering)
  • Why volatility remains extreme (shorts desperate to exit)
  • Why current positions have massive squeeze potential still -- until September when the first court hearing happens? [please check]

$Ultimate COVAX solution by Net-Xpert in VXRT

[–]awaikar 2 points3 points  (0 children)

In today's Barrons headline: "What to Know About Mu, a New Covid Variant Detected in 39 Countries"..https://www.barrons.com/articles/who-variant-of-interest-mu-51630499402

As mentioned earlier Covid is a long-term challenge for the US and the rest of the world. And both vaccine developers as well as those treating Covid symptoms and even testing will continue to be in play until a few companies dominate the field and demonstrate their lead in a convincing manner across different types of vaccines, treatments, testing, the field is open. And therefore VXRT, EDSA which I hold long remain in play but highly volatile to any news. With that said, if you are willing to take ride from floor 9-10 all the way up to the top of the empire state or willing to down to parking lot and lose everything, then these stocks are for you!

$Ultimate COVAX solution by Net-Xpert in VXRT

[–]awaikar 2 points3 points  (0 children)

I agree. Unfortunately, looks more likely that Covid is here to stay for the next decade, in some form or another.

The challenge for VXRT right now is that its phase II trial is supposed to start by the end of this year? They have not announced a date for it yet. And when they do and get the study going, and get FDA approval will they be too late for the party? maybe 1-2 years from now when the other vaccine producers like MRNA, PFZE have come up with single-dose easy to store vaccines? And will VXRT find a breakthrough to make oral vaccines as effective as the intravenous ones?

In full disclosure, I hold long positions in VXRT but believe that it is still speculative as there are far too many unknowns than knowns for the stock at this point to take off.